Medicine details

Long-term female contraception. Each subcutaneous injection prevents ovulation and provides contraception for at least 13 weeks (+/- 1 week). However, it should be taken into consideration that the return to fertility (ovulation) may be delayed for up to one year. Since loss of bone mineral density (BMD) may occur in females of all ages who use Sayana® Press long-term, a risk/benefit assessment, which also takes into consideration the decrease in BMD that occurs during pregnancy and/or lactation, should be considered. In adolescents, use of Sayana® Press is only indicated when other contraceptive methods are considered unsuitable or unacceptable, due to unknown long-term effects of bone loss associated with Sayana® Press during the critical period of bone accretion. Sayana® Press has not been studied in women under the age of 18 years but data is available for intramuscular medroxyprogesterone acetate in this population